Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Interim Update from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

John M. Pagel,Franck Morschhauser,Tilly Herve,Aristeidis Chaidos,Tycel Phillips,Vincent Ribrag,Phillip Campbell,Christophe Fruchart,Wojciech Jurczak,Pamela McKay,Stephen Opat,John Radford,Alice McDonald,Haley Howell,Kate J. Newberry, Mark Woodruff,Alicia Clawson,John Larus,Stephen J. Blakemore,Harry Miao,Gilles Salles

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2018）

Cited 7|Views30
No score
Abstract
Tazemetostat, a potent, selective, oral EZH2 inhibitor has shown antitumor activity in a phase 1 study that included NHL patients with mutated (mt) or wild-type (wt) EZH2 tumors, providing rationale for further investigation.
More
Translated text
Key words
Non-Hodgkin Lymphoma,Follicular lymphoma,EZH2,EZH2 inhibitor
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined